JP2024515344A5 - - Google Patents
Info
- Publication number
- JP2024515344A5 JP2024515344A5 JP2023564255A JP2023564255A JP2024515344A5 JP 2024515344 A5 JP2024515344 A5 JP 2024515344A5 JP 2023564255 A JP2023564255 A JP 2023564255A JP 2023564255 A JP2023564255 A JP 2023564255A JP 2024515344 A5 JP2024515344 A5 JP 2024515344A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- item
- composition according
- pharmaceutically acceptable
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025066627A JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163177254P | 2021-04-20 | 2021-04-20 | |
| US63/177,254 | 2021-04-20 | ||
| PCT/US2022/025648 WO2022226127A1 (en) | 2021-04-20 | 2022-04-20 | Compositions and methods for inhibiting complement component 3 expression |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066627A Division JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515344A JP2024515344A (ja) | 2024-04-09 |
| JP2024515344A5 true JP2024515344A5 (cg-RX-API-DMAC10.html) | 2025-04-23 |
Family
ID=83723122
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023564255A Pending JP2024515344A (ja) | 2021-04-20 | 2022-04-20 | 補体成分３の発現を阻害するための組成物及び方法 |
| JP2025066627A Pending JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025066627A Pending JP2025100729A (ja) | 2021-04-20 | 2025-04-15 | 補体成分３の発現を阻害するための組成物及び方法 |
Country Status (12)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI868755B (zh) | 2022-06-24 | 2025-01-01 | 丹麥商諾佛 儂迪克股份有限公司 | 抑制跨膜絲胺酸蛋白酶６（ｔｍｐｒｓｓ６）表現的組成物及方法 |
| CN118202053A (zh) * | 2023-02-17 | 2024-06-14 | 苏州时安生物技术有限公司 | 一种调节补体C3表达的siRNA、其缀合物和药物组合物及用途 |
| EP4747385A1 (en) * | 2023-07-21 | 2026-05-27 | Shanghai Argo Biopharmaceutical Co., Ltd. | Compositions and methods for inhibiting expression of complement component 3 (c3) |
| WO2025168134A1 (zh) * | 2024-02-08 | 2025-08-14 | 北京安龙生物医药有限公司 | 靶向补体成分c3基因的寡核苷酸及其用途 |
| CN121592644A (zh) * | 2024-08-16 | 2026-03-03 | 施能康生物医药（苏州）有限公司 | 靶向C3补体的RNAi试剂及其用途 |
| WO2026145589A1 (zh) * | 2025-01-03 | 2026-07-09 | 成都先衍生物技术有限公司 | 一种同时抑制C3与C5基因表达的dsRNA缀合物及其用途 |
| CN121154665B (zh) * | 2025-11-21 | 2026-02-27 | 天津医科大学第二医院 | 尿苷在防治糖尿病肾病药物开发过程中及药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2305813A3 (en) * | 2002-11-14 | 2012-03-28 | Dharmacon, Inc. | Fuctional and hyperfunctional sirna |
| CN101426913A (zh) * | 2005-11-30 | 2009-05-06 | 因特拉迪格姆公司 | 使用siRNA敲减基因表达和改善实体器官和细胞移植的组合物和方法 |
| WO2010033225A2 (en) * | 2008-09-22 | 2010-03-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the specific inhibition of gene expression by dsrna possessing modifications |
| WO2010042755A2 (en) * | 2008-10-08 | 2010-04-15 | Chimeros Inc. | Chimeric therapeutics, compositions, and methods for using same |
| WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| EP3526328A4 (en) * | 2016-10-17 | 2020-05-27 | Apellis Pharmaceuticals, Inc. | COMBINATION THERAPY FOR C3 INHIBITION |
| CA3078971A1 (en) * | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| CN112368381A (zh) * | 2018-04-18 | 2021-02-12 | 迪克纳制药公司 | 用于治疗高胆固醇血症和相关病况的pcsk9靶向寡核苷酸 |
| WO2020104669A1 (en) * | 2018-11-23 | 2020-05-28 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| WO2021037941A1 (en) * | 2019-08-27 | 2021-03-04 | Silence Therapeutics Gmbh | Nucleic acids for inhibiting expression of c3 in a cell |
| CA3158320A1 (en) * | 2019-10-22 | 2021-04-29 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| MX2022009870A (es) * | 2020-02-14 | 2022-11-07 | Apellis Pharmaceuticals Inc | Ácidos ribonucleicos (arn) para la inhibición del complemento. |
| CN116761616A (zh) * | 2021-01-22 | 2023-09-15 | 阿耐拉姆制药公司 | 经修饰的双链寡核苷酸 |
| EP4346844A4 (en) * | 2021-05-26 | 2025-09-10 | Apellis Pharmaceuticals Inc | TREATMENT OF COMPLEMENT-MEDIATED DISORDERS |
-
2022
- 2022-04-20 IL IL307721A patent/IL307721A/en unknown
- 2022-04-20 JP JP2023564255A patent/JP2024515344A/ja active Pending
- 2022-04-20 BR BR112023021703A patent/BR112023021703A2/pt unknown
- 2022-04-20 CN CN202280034163.4A patent/CN117295819A/zh active Pending
- 2022-04-20 AU AU2022261922A patent/AU2022261922A1/en active Pending
- 2022-04-20 US US18/287,260 patent/US20250002908A1/en active Pending
- 2022-04-20 MX MX2023012385A patent/MX2023012385A/es unknown
- 2022-04-20 EP EP22792454.5A patent/EP4326876A4/en active Pending
- 2022-04-20 KR KR1020237036421A patent/KR20230173116A/ko active Pending
- 2022-04-20 CA CA3177629A patent/CA3177629A1/en active Pending
- 2022-04-20 WO PCT/US2022/025648 patent/WO2022226127A1/en not_active Ceased
-
2023
- 2023-10-30 CO CONC2023/0014681A patent/CO2023014681A2/es unknown
-
2025
- 2025-04-15 JP JP2025066627A patent/JP2025100729A/ja active Pending